Uncategorized
STAT+: Pharmalittle: We’re reading about FDA seeking new powers over DTC ads, an EU pledge to fight AMR, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup of stimulation. Our choice today is orange creme. Meanwhile, here are some items of interest to get you going. We hope you have a meaningful and productive day, and conquer the world. Best of luck…
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax’s upcoming annual meeting, renewing pressure for changes at the vaccine maker, Reuters writes. In a letter to the company, hedge fund founder Himanshu Shah said management has failed to implement aggressive cost-cutting measures and urged leadership to reduce costs and opportunistically buy back 10 million to 20 million shares. Shah Capital, which owns 9% of Novavax and is its second-largest shareholder, has been pushing the board to pursue strategic changes, including a potential sale. The firm wants a like-minded strategic long-term investor to take a 10% to 20% ownership stake to reshape the company. In its letter, the firm said a partnership with Sanofi has not benefited Novavax.
The U.S. Food and Drug Administration is seeking new powers to hold companies accountable for misleading direct-to-consumer ads, adding legislative weight to its pushback against deceptive drug advertising, Fierce Pharma explains. Last year, President Trump ordered the agency to ensure companies provide balanced information on the benefits and risks of drugs in DTC ads. Days later, the agency published letters alleging violations of federal pharma marketing rules by companies including Bristol Myers Squibb, Eli Lilly and Novartis. The FDA has continued to send letters to companies accused of breaking the rules. Now, the FDA has included its 2027 budget proposal to request new powers to regulate DTC ads. The agency said it “needs additional authorities to more effectively address DTC advertising that lacks fair balance and is frequently misleading and confusing to consumers and patients.”
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this far. It is an accomplishment, after all. The next step is to … keep going. And why not? Just consider the alternatives. On that optimistic note, please join us for a needed cup of stimulation. Our choice today is orange creme. Meanwhile, here are some items of interest to get you going. We hope you have a meaningful and productive day, and conquer the world. Best of luck…
Activist investor Shah Capital plans to vote against the re-election of board nominees and the executive compensation package at Novavax’s upcoming annual meeting, renewing pressure for changes at the vaccine maker, Reuters writes. In a letter to the company, hedge fund founder Himanshu Shah said management has failed to implement aggressive cost-cutting measures and urged leadership to reduce costs and opportunistically buy back 10 million to 20 million shares. Shah Capital, which owns 9% of Novavax and is its second-largest shareholder, has been pushing the board to pursue strategic changes, including a potential sale. The firm wants a like-minded strategic long-term investor to take a 10% to 20% ownership stake to reshape the company. In its letter, the firm said a partnership with Sanofi has not benefited Novavax.
The U.S. Food and Drug Administration is seeking new powers to hold companies accountable for misleading direct-to-consumer ads, adding legislative weight to its pushback against deceptive drug advertising, Fierce Pharma explains. Last year, President Trump ordered the agency to ensure companies provide balanced information on the benefits and risks of drugs in DTC ads. Days later, the agency published letters alleging violations of federal pharma marketing rules by companies including Bristol Myers Squibb, Eli Lilly and Novartis. The FDA has continued to send letters to companies accused of breaking the rules. Now, the FDA has included its 2027 budget proposal to request new powers to regulate DTC ads. The agency said it “needs additional authorities to more effectively address DTC advertising that lacks fair balance and is frequently misleading and confusing to consumers and patients.”
Uncategorized
Opinion: What happens when a chief executive loses executive functions?
Circa 1970, the renowned Russian neuropsychologist Alexander Luria together with Karl Pribram from Stanford University and other neuroscientists of that era introduced the term “executive functions” into the scientific lexicon to denote complex behaviors such as attention and awareness. They identified the frontal lobe — the front of the brain — as the “executive of the brain” responsible for these behaviors based on their experiments with primates and patients with specific brain injuries.
Over time, the concept evolved to include mental processes needed to focus, concentrate, and pay attention when challenged by multiple simultaneous sources of information to weigh options and make informed decisions as opposed to impulsive ones.
Circa 1970, the renowned Russian neuropsychologist Alexander Luria together with Karl Pribram from Stanford University and other neuroscientists of that era introduced the term “executive functions” into the scientific lexicon to denote complex behaviors such as attention and awareness. They identified the frontal lobe — the front of the brain — as the “executive of the brain” responsible for these behaviors based on their experiments with primates and patients with specific brain injuries.
Over time, the concept evolved to include mental processes needed to focus, concentrate, and pay attention when challenged by multiple simultaneous sources of information to weigh options and make informed decisions as opposed to impulsive ones.
Uncategorized
As Duchenne innovation booms, let’s ensure it becomes real progress
At Sarepta Therapeutics, we’ve seen it all. Here are the questions I believe we should be asking to move forward in Duchenne muscular dystrophy.
Uncategorized
CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies
Freudenberg Medical, a Kaiserslautern, Germany-based contract design manufacturing partner, launched CleanAssure, a new ISO Class 5 controlled cleanroom designed to deliver clean and sterile single-use assemblies for biopharmaceutical customers, according to the company.
Freudenberg Medical manufactures silicone and thermoplastic elastomer (TPE) tubing for bioprocessing and critical fluid transfer. The company specializes in seamless, overmolded single-use assemblies used in vaccine production, cell cultivation, fluid transfer, and fill-finish operations.
The controlled cleanroom enables customers to receive ready-to-use washed, dried, and gamma sterilized single-use assemblies with the highest product quality, sterility, and process consistency, noted Rudi Gall, vp, global pharma, Freudenberg Medical.
“CleanAssure allows us to support our customers beyond component manufacturing,” he said. “By integrating controlled cleaning and sterilization into our single-use assembly services, we help reduce contamination risk, streamline validation activities, and support a reliable supply for our customers. We can now support customers with their entire component value chain and allow them to focus on their core manufacturing capability.”
Freudenberg’s cleaning process uses ultrapure water and air, operating within ISO 5 conditions. The water is produced using a multi-stage filtration process, resulting in high-purity water specifically suitable for pharmaceutical applications.
Key biopharma industry challenges
Biopharmaceutical manufacturers increasingly rely on single-use systems but face ongoing challenges related to cleaning validation, contamination risk, and production downtime. Customer-managed cleaning processes are often time-intensive, costly, and require additional resources while directly impacting supply reliability, according to Gall.
The company explained that its controlled cleaning environment addresses these challenges by reducing cross-contamination risk through tightly controlled ISO Class 5 processing; alleviating customer cleaning validation burden by delivering assemblies washed and sterilized under cGMP, validated conditions; minimizing production downtime by removing cleaning as a process step; and supporting a consistent, reliable supply of high-quality single-use assemblies.
Freudenberg will be attending INTERPHEX New York, April 21–23, Booth 1673, to exhibit its new products and services.
The post CleanAssure Launched as an ISO Class 5 Controlled Cleanroom for Sterile Single-Use Assemblies appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoDisney’s live-action Aladdin finally finds its stars